Clinical trial
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has…
NCT00234039 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00234039 |
|---|---|
| Title | S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin |
| Official title | Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride |
| Enrollment | 58 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2011 |
| Completion | Apr 1, 2013 |
| First posted | Oct 6, 2005 |
| Last update posted | Jan 8, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: